CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 0.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02544607
NCT02544607Phase 4Completed
CompareCT.gov

Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression

Massachusetts General Hospital·interventional·Posted Sep 9, 2015·Updated Apr 16, 2019

In Brief

A Phase 4 clinical trial evaluating Ketamine and Magnetic Resonance Imaging (MRI) for Depression and 2 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine for patients with depression to examine the extent to which certain brain areas predict ketamine's antidepressant effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Anxious Depression, Major Depressive Disorder
CountriesUnited States
CollaboratorsBrain & Behavior Research Foundation, National Institutes of Health (NIH)

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 9, 2015
Enrollment StartMar 1, 2016
Primary CompletionDec 29, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.8 years ago

Interventions

Ketaminedrug

Ketamine 0.5mg/kg over 40 minutes IV

Magnetic Resonance Imaging (MRI)other

MRI technology will be used before and after ketamine for patients with depression